表柔比星联合紫杉醇治疗三阴性乳腺癌效果研究.docVIP

表柔比星联合紫杉醇治疗三阴性乳腺癌效果研究 　　【摘要】 目的 探讨表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果。方法 50例三阴性乳腺癌患者， 依照随机抽签原则分为治疗组和对照组， 各25例。治疗组应用表柔比星联合紫杉醇治疗， 对照组单独应用表柔比星治疗。对比两组患者的治疗效果与治疗前后肿瘤直径变化。结果 治疗组患者中完全缓解10例， 部分缓解11例， 稳定3例， 进展1例， 治疗有效率为84.0%（21/25）；对照组中完全缓解4例， 部分缓解10例， 稳定7例， 进展4例， 治疗有效率为56.0%（14/25）；两组治疗有效率对比差异具有统计学意义（P0.05）。治疗后， 治疗组肿瘤直径为（1.9±0.6）cm， 对照组肿瘤直径为（3.2±0.7）cm， 对比差异有统计学意义（t=7.050， P=0.0000.05）。结论 表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果确切， 能有效缩小肿瘤组织， 可作为三阴性乳腺癌患者理想用药方案。 　　【关键词】 表柔比星；紫杉醇；三阴性乳腺癌 　　DOI：10.14163/j.cnki.11-5547/r.2016.32.070 　　【Abstract】 Objective To investigate clinical effect by pharmorubicin combined with paclitaxel in the treatment of triple negative breast cancer. Methods A total of 50 patients with triple negative breast cancer were randomly divided into treatment group and control group， with 25 cases in each group. The treatment group received pharmorubicin combined with paclitaxel for treatment， and the control group received single pharmorubicin for treatment. Comparison was made on curative effects and diameter of tumor before and after treatment between the two groups. Results There were 10 complete remission cases， 11 partial remission cases， 3 stable cases and 1 progress case in the treatment group， with effective rate as 84.0% （21/25）. The control group received 4 complete remission cases， 10 partial remission cases， 7 stable cases and 4 progress cases， with effective rate as 56.0% （14/25）. The difference of effective rate had statistical significance between the two groups （P0.05）. After treatment， the treatment group had diameter of tumor as （1.9±0.6） cm and the control group as （3.2±0.7） cm， and their difference had statistical significance （t=7.050， P=0.0000.05）. Conclusion Combination of pharmorubicin and paclitaxel provides affirmative clinical effect in treating triple negative breast cancer. This method can effectively lessen tumor tissue， and it can act as an ideal medication regimen for triple negative breast cancer patients. 　　【Key words】 Pharmorubicin； Paclitaxel； Trip